Roche Holding (ROG.SW) Stock Price

Roche Holding Price

SIX·CLOSED
363.40CHF+43.40 (+12.70 %)
Market closed

Revenue has compounded at 2.0% per year over the past 19 years to 61.52 B CHF. Earnings per share have grown at 3.0% per year over the last 19 years. Roche Holding's net margin stands at 20.9%, down from 22.2% several years earlier. Roche Holding currently offers a dividend yield of about 2.67%. The payout ratio is around 60% of earnings. The dividend has grown at 7.4% per year over the past 19 years. The stock trades about 43% above its 52-week low.

Roche Holding stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Roche Holding over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Roche Holding stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Roche Holding's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Roche Holding Stock Price History
DateRoche Holding Price
8/19/2026363.40 CHF
5/13/2026320.00 CHF
5/12/2026321.50 CHF
5/11/2026319.40 CHF
5/8/2026315.30 CHF
5/7/2026318.30 CHF
5/6/2026321.90 CHF
5/5/2026318.50 CHF
5/4/2026316.50 CHF
4/30/2026318.40 CHF
4/29/2026317.30 CHF
4/28/2026321.10 CHF
4/27/2026321.20 CHF
4/24/2026322.00 CHF
4/23/2026324.90 CHF
4/22/2026313.10 CHF
4/21/2026317.20 CHF
4/20/2026320.90 CHF
4/17/2026320.00 CHF
4/16/2026313.50 CHF
4/15/2026317.00 CHF
4/14/2026318.10 CHF
4/13/2026317.20 CHF
4/10/2026315.60 CHF
4/9/2026316.70 CHF
4/8/2026314.10 CHF
4/7/2026311.30 CHF
4/2/2026318.00 CHF
4/1/2026318.30 CHF
3/31/2026314.70 CHF
3/30/2026314.10 CHF
3/27/2026312.50 CHF
3/26/2026312.80 CHF
3/25/2026312.00 CHF
3/24/2026305.80 CHF
3/23/2026303.90 CHF
3/20/2026300.90 CHF
3/19/2026305.70 CHF
3/18/2026314.80 CHF
3/16/2026320.18 CHF
3/13/2026323.04 CHF
3/12/2026319.05 CHF
3/11/2026330.18 CHF
3/10/2026332.40 CHF
3/9/2026330.50 CHF
3/6/2026341.98 CHF
3/5/2026358.80 CHF
2/27/2026367.60 CHF
2/26/2026369.10 CHF
2/25/2026369.60 CHF
2/23/2026367.94 CHF
2/20/2026368.20 CHF
2/19/2026369.30 CHF
2/18/2026369.22 CHF
2/17/2026361.40 CHF
2/16/2026360.00 CHF
2/14/2026360.00 CHF
2/13/2026360.00 CHF
2/12/2026359.35 CHF
2/11/2026351.10 CHF
2/10/2026351.10 CHF
2/9/2026353.89 CHF
2/6/2026353.24 CHF
2/5/2026360.60 CHF
2/4/2026360.05 CHF
2/3/2026354.50 CHF
2/2/2026350.70 CHF
1/30/2026347.00 CHF
1/29/2026346.91 CHF
1/28/2026350.00 CHF
1/27/2026352.84 CHF
1/26/2026348.10 CHF
1/23/2026347.90 CHF
1/22/2026344.70 CHF
1/21/2026344.70 CHF
1/20/2026346.80 CHF
1/19/2026348.90 CHF
1/16/2026345.70 CHF
1/15/2026345.62 CHF
1/14/2026344.64 CHF
1/13/2026342.50 CHF
1/12/2026342.50 CHF
1/9/2026339.40 CHF
1/8/2026338.77 CHF
1/7/2026334.29 CHF
1/6/2026327.45 CHF
1/5/2026325.17 CHF
1/2/2026328.20 CHF
12/30/2025328.78 CHF
12/29/2025329.60 CHF
12/24/2025329.24 CHF
12/23/2025329.60 CHF
12/22/2025325.50 CHF
12/19/2025324.93 CHF
12/18/2025317.00 CHF
12/17/2025320.40 CHF
12/16/2025321.90 CHF
12/15/2025316.80 CHF
12/12/2025317.90 CHF
12/11/2025318.70 CHF
12/10/2025321.33 CHF
12/9/2025317.70 CHF
12/8/2025317.70 CHF
12/6/2025311.84 CHF
12/5/2025310.90 CHF
12/4/2025312.72 CHF
12/3/2025313.38 CHF
12/2/2025313.30 CHF
12/1/2025308.25 CHF
11/28/2025308.36 CHF
11/27/2025312.90 CHF
11/26/2025313.60 CHF
11/25/2025311.62 CHF
11/24/2025310.90 CHF
11/21/2025314.61 CHF
11/20/2025311.56 CHF
11/19/2025310.44 CHF
11/18/2025304.10 CHF
11/17/2025287.14 CHF
11/15/2025287.35 CHF
11/14/2025286.10 CHF
11/13/2025290.40 CHF
11/12/2025288.70 CHF
11/11/2025278.90 CHF
11/10/2025279.13 CHF
11/7/2025267.11 CHF
11/6/2025264.60 CHF
11/5/2025262.68 CHF
11/4/2025263.22 CHF
11/3/2025260.50 CHF
10/31/2025260.08 CHF
10/30/2025260.78 CHF
10/29/2025260.76 CHF
10/28/2025262.24 CHF
10/27/2025267.42 CHF
10/25/2025269.13 CHF
10/24/2025271.20 CHF
10/23/2025271.38 CHF
10/22/2025279.74 CHF
10/21/2025279.53 CHF
10/20/2025279.26 CHF
10/17/2025282.56 CHF
10/16/2025284.63 CHF
10/15/2025281.28 CHF
10/14/2025290.10 CHF
10/13/2025290.20 CHF
10/10/2025293.60 CHF
10/9/2025291.30 CHF
10/8/2025288.50 CHF
10/7/2025288.40 CHF
10/6/2025286.80 CHF
10/3/2025284.30 CHF
10/2/2025282.30 CHF
10/1/2025259.90 CHF
9/30/2025259.90 CHF
9/29/2025256.10 CHF
9/26/2025253.50 CHF
9/25/2025255.00 CHF
9/24/2025263.10 CHF
9/23/2025266.56 CHF
9/22/2025270.01 CHF
9/19/2025265.42 CHF
9/18/2025260.49 CHF
9/17/2025258.12 CHF
9/16/2025258.99 CHF
9/15/2025262.20 CHF
9/12/2025266.24 CHF
9/11/2025268.29 CHF
9/10/2025266.10 CHF
9/9/2025269.45 CHF
9/8/2025270.17 CHF
9/5/2025274.20 CHF
9/4/2025274.91 CHF
9/3/2025267.97 CHF
9/2/2025262.84 CHF
9/1/2025262.30 CHF
8/29/2025260.41 CHF
8/28/2025261.00 CHF
8/27/2025259.20 CHF
8/26/2025259.90 CHF
8/25/2025261.50 CHF
8/22/2025262.50 CHF
8/21/2025262.40 CHF
8/20/2025262.21 CHF
8/19/2025256.00 CHF
Access this data via the Eulerpool API
Get Free API Key

Roche Holding Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
60.44 B CHF
15.40 B CHF
11.50 B CHF
Jan 1, 2024
62.40 B CHF
13.42 B CHF
8.28 B CHF
Jan 1, 2025
61.52 B CHF
19.26 B CHF
12.88 B CHF
Jan 1, 2026 (e)
62.80 B CHF
20.24 B CHF
16.17 B CHF
Jan 1, 2027 (e)
65.41 B CHF
21.08 B CHF
17.41 B CHF
Jan 1, 2028 (e)
68.79 B CHF
22.17 B CHF
19.07 B CHF
Jan 1, 2029 (e)
73.09 B CHF
23.55 B CHF
21.05 B CHF
Jan 1, 2030 (e)
77.67 B CHF
25.03 B CHF
23.72 B CHF

Roche Holding Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 3:39 PM
 
REVENUEB CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CHF
EBITB CHF
EBIT MARGIN%
NET INCOMEB CHF
NET INCOME GROWTH%
DIV.CHF
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
52.6455.7559.5063.7558.3262.8065.8160.4462.4061.5262.8065.4168.7973.0977.6781.76
4.435.916.737.15-8.517.684.80-8.163.23-1.412.094.155.166.266.265.26
71.3571.5072.2372.7371.9668.6372.7472.9473.9073.5373.5373.5373.5373.5373.5373.53
37.5639.8642.9846.3741.9743.1047.8844.0846.1145.2446.1848.1050.5853.7557.1160.12
16.8517.3018.9221.0318.4017.7017.4815.4013.4219.2620.2421.0822.1723.5525.03–
32.0131.0331.8032.9931.5628.1826.5525.4721.5031.3232.2232.2232.2232.2232.22–
9.588.6310.5013.5014.3013.9312.4211.508.2812.8816.1717.4119.0721.0523.7224.33
8.04-9.8521.6328.545.91-2.55-10.83-7.43-28.0155.6125.527.669.5510.4112.682.55
8.108.208.308.709.009.109.309.509.609.709.809.9510.09–––
1.251.231.224.823.451.112.202.151.051.041.031.531.41–––
859.00860.00861.00865.77863.70857.47799.18804.00802.00803.00803.00803.00803.00803.00803.00803.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Roche Holding generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Roche Holding retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Roche Holding's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Roche Holding has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Roche Holding's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Roche Holding stock margins

The Roche Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Roche Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Roche Holding.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
68.63 %
28.18 %
22.18 %
Jan 1, 2022
72.74 %
26.55 %
18.87 %
Jan 1, 2023
72.94 %
25.47 %
19.02 %
Jan 1, 2024
73.90 %
21.50 %
13.27 %
Jan 1, 2025
73.53 %
31.32 %
20.94 %
Jan 1, 2026 (e)
73.53 %
32.22 %
25.74 %
Jan 1, 2027 (e)
73.53 %
32.22 %
26.61 %
Jan 1, 2028 (e)
73.53 %
32.22 %
27.72 %

Roche Holding Stock Revenue, EBIT, Earnings per Share

The Roche Holding earnings per share therefore indicates how much revenue Roche Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
73.24 CHF
20.64 CHF
16.25 CHF
Jan 1, 2022
82.35 CHF
21.87 CHF
15.54 CHF
Jan 1, 2023
75.18 CHF
19.15 CHF
14.30 CHF
Jan 1, 2024
77.80 CHF
16.73 CHF
10.32 CHF
Jan 1, 2025
76.61 CHF
23.99 CHF
16.04 CHF
Jan 1, 2026 (e)
78.21 CHF
25.20 CHF
20.13 CHF
Jan 1, 2027 (e)
81.46 CHF
26.25 CHF
21.68 CHF
Jan 1, 2028 (e)
85.66 CHF
27.60 CHF
23.75 CHF

Roche Holding business model & stock analysis

Roche Holding SWOT Analysis

Strengths

Roche Holding AG has several strengths that contribute to its success:

  • Strong brand reputation and recognition in the pharmaceutical industry.
  • Diverse portfolio of innovative and life-saving drugs.
  • Extensive research and development capabilities.
  • Global presence with a wide network of subsidiaries and partnerships.
  • Highly skilled and experienced workforce.
  • Strong financial performance with consistent revenue growth.

Weaknesses

While Roche has many strengths, it also faces certain weaknesses:

  • Dependence on a few key drugs for a significant portion of its revenue.
  • High costs associated with drug development and clinical trials.
  • Regulatory hurdles and the risk of litigation in the pharmaceutical industry.
  • Relatively low diversification outside the pharmaceutical sector.
  • Vulnerable to fluctuations in exchange rates and economic conditions.

Opportunities

Roche Holding AG can capitalize on the following opportunities:

  • Increasing global demand for personalized medicine and targeted therapies.
  • Expanding into emerging markets with growing healthcare needs.
  • Investing in digital health and innovative technologies.
  • Acquiring or partnering with smaller biotech companies for portfolio expansion.
  • Collaborating with research institutions and academia for breakthrough discoveries.

Threats

Roche Holding AG should be cautious of the following threats:

  • Intense competition from other pharmaceutical giants.
  • Loss of patent protection and entry of generic competitors.
  • Increasing regulatory scrutiny and pricing pressures.
  • Political and legal uncertainties affecting international operations.
  • Rapidly evolving technological landscape disrupting traditional business models.

Roche Holding Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Roche Holding historical P/E ratio, EBIT multiple, and P/S ratio

Roche Holding annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Roche Holding shares outstanding

The number of shares of Roche Holding was 803 M in 2025. This indicates how many shares Roche Holding is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
857.47 M Stocks
Jan 1, 2022
799.18 M Stocks
Jan 1, 2023
804.00 M Stocks
Jan 1, 2024
802.00 M Stocks
Jan 1, 2025
803.00 M Stocks
Jan 1, 2026 (e)
803.00 M Stocks
Jan 1, 2027 (e)
803.00 M Stocks
Jan 1, 2028 (e)
803.00 M Stocks

Roche Holding stock splits

In Roche Holding's history, there have been no stock splits.

Roche Holding Dividend History

36 years of dividend payments · 23 consecutive increases

YearAnnual DividendYoY ChangePayments
20269.80CHFYTD—1×
Mar 12, 20269.80CHF↑ 1.0%1/1
20259.70CHF↑ 1.0%1×
Mar 27, 20259.70CHF↑ 1.0%1/1
20249.60CHF↑ 1.1%1×
20239.50CHF↑ 2.2%1×
20229.30CHF↑ 2.2%1×
20219.10CHF↑ 1.1%1×
20209.00CHF↑ 3.4%1×
20198.70CHF↑ 4.8%1×
20188.30CHF↑ 1.2%1×
20178.20CHF↑ 1.2%1×

Roche Holding dividend history and estimates

In 2025, Roche Holding paid a dividend amounting to 9.70 CHF. Dividend means that Roche Holding distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
9.10 CHF
0.00 CHF
Jan 1, 2022
9.30 CHF
0.00 CHF
Jan 1, 2023
9.50 CHF
0.00 CHF
Jan 1, 2024
9.60 CHF
0.00 CHF
Jan 1, 2025
9.70 CHF
0.00 CHF
Jan 1, 2026
9.80 CHF
0.00 CHF
Jan 1, 2027 (e)
0.00 CHF
9.95 CHF
Jan 1, 2028 (e)
0.00 CHF
10.09 CHF

Roche Holding dividend payout ratio

In 2025, Roche Holding had a payout ratio of 60.47%. The payout ratio indicates the percentage of the company's profits that Roche Holding distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
56.02 %
Jan 1, 2022
59.84 %
Jan 1, 2023
66.43 %
Jan 1, 2024
93.02 %
Jan 1, 2025
60.47 %
Jan 1, 2026 (e)
48.67 %
Jan 1, 2027 (e)
45.89 %
Jan 1, 2028 (e)
42.51 %
Price targets and forecasts for Roche Holding are not yet available.

Roche Holding Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
1/31/20248.20CHF-29.52 BCHF-2023 Q4
7/19/202311.46CHF-32.24 BCHF-2023 Q2
2/1/20239.14CHF-32.30 BCHF-2022 Q4
7/21/202211.12CHF-30.93 BCHF-2022 Q2
2/3/20229.81CHF-32.20 BCHF-2021 Q4
7/22/202110.41CHF-30.67 BCHF-2021 Q2
2/4/20218.93CHF-30.95 BCHF-2020 Q4
7/23/202010.73CHF-30.66 BCHF-2020 Q2
1/30/20209.07CHF-32.32 BCHF-2019 Q4
7/25/201910.79CHF-30.01 BCHF-2019 Q2

EESG©

Eulerpool ESG Scorecard© for the Roche Holding stock

96/100
99
Environment
99
Social
91
Governance
E

Environment

20
Scope 1 - Direct Emissions245,832
Scope 2 - Indirect emissions from purchased energy69,198
Scope 3 - Indirect emissions within the value chain5,478,525
Total CO₂ emissions315,030
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees51.1
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Roche Holding shareholder structure

% Name
3.11665%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.24901%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.93169%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
1.79956%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.50661%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
1.35183%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
...

Roche Holding Beneficial Ownership Filings (SEC 13D/G)

Free Float
90.7%
Float Shares
-
Shares Outstanding
-

Roche Holding Executives and Management Board

25 members · avg. age 57 · 40 % women

TS

Dr. Thomas Schinecker (50)

Chief Executive Officer, Member of the Corporate Executive Committee

9.61 M CHF

Management

AH

Dr. Alan Hippe (58)

Chief Financial Officer, Member of the Corporate Executive Committee

6.07 M CHF
TG

Ms. Teresa Graham (52)

Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals

6.06 M CHF
CW

Ms. Cristina Wilbur (58)

Member of the Corporate Executive Committee, Chief People Officer

4.31 M CHF
MS

Mr. Matt Sause (48)

Member of the Corporate Executive Committee, Chief Executive Officer of Roche Diagnostics

4.26 M CHF
WM

Ms. Wafaa Mamilli (57)

Chief Digital Technology Officer, Member of the Executive Committee

–
PS

Mr. Pascale Schmidt (52)

Chief Compliance Officer

–

Board of Directors

Dr. Severin Schwan

Dr. Severin Schwan (58)

Non-Executive Chairman of the Board · since 2006

5.69 M CHF
AH

Mr. Andre Hoffmann (65)

Non-Executive Independent Vice Chairman of the Board

400,000.00 CHF
JD

Dr. Joerg Duschmale (41)

Non-Executive Independent Director

394,602.00 CHF
CD

Dr. Claudia Dyckerhoff (58)

Non-Executive Independent Director

367,341.00 CHF
AH

Ms. Anita Hauser (56)

Non-Executive Independent Director

367,202.00 CHF
PF

Dr. Patrick Frost (57)

Non-Executive Independent Director

360,000.00 CHF

Frequently asked questions about Roche Holding

29 analysts currently rate the Roche Holding stock: 15 recommend buying, 9 holding and 5 selling. For 2026, analysts expect Roche Holding to generate revenue of 62.80 B CHF and earnings per share of 20.13 CHF.

Roche Holding Analyst Price Targets 2026

Converted at the current exchange rate, the Roche Holding share trades at 386.39 EUR (363.40 CHF).

The Roche Holding share (ROG.SW) is listed on 7 stock exchanges, including: Frankfurt (RHO5.F), München (RHO5.MU), Düsseldorf (RHO5.DU), Hamburg (RHO5.HM), London (0QOK.L), SIX (Zürich) (ROG.SW).

No history available for Roche Holding.

The expected revenue of Roche Holding is 62.80 B CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Roche Holding is 16.17 B CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Roche Holding is currently 18.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Roche Holding stock.

The price-to-sales ratio (P/S) of Roche Holding is currently 4.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Roche Holding stock.

The Eulerpool Quality Score for Roche Holding is 4/10.

The ISIN of Roche Holding is CH1499059983. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Roche Holding is 855167. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Roche Holding is ROG.SW. The ticker symbol is used to trade Roche Holding shares on the stock exchange.

Over the past 12 months, Roche Holding paid a dividend of 9.70 CHF . This corresponds to a dividend yield of about 2.67 %. For the coming 12 months, Roche Holding is expected to pay a dividend of 9.95 CHF.

The current dividend yield of Roche Holding is 2.67 %.

Roche Holding pays a dividend, distributed in the months of , , , .

Roche Holding paid dividends every year for the past 35 years.

For the upcoming 12 months, dividends amounting to 9.95 CHF are expected. This corresponds to a dividend yield of 3.11 %.

Roche Holding is assigned to the 'Health' sector.

To receive the latest dividend of Roche Holding from amounting to 9.8 CHF, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Roche Holding distributed 9.6 CHF as dividends.

The dividends of Roche Holding are distributed in CHF.

All fundamentals and in-depth analysis of Roche Holding

Our stock analysis for Roche Holding stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roche Holding. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Roche Holding Stock
Roche Holding Revenue→
Roche Holding Stock
Roche Holding Net Income→
Roche Holding Stock
Roche Holding P/E→
Roche Holding Stock
Roche Holding P/S→
Roche Holding Stock
Roche Holding EBIT→
Roche Holding Stock
Roche Holding Dividend→
Roche Holding Stock
Roche Holding Directors Dealings→
Roche Holding Stock
Roche Holding Stocks→
Roche Holding Stock
Roche Holding Market capitalization→
Roche Holding Stock
Roche Holding Debt→
Roche Holding Stock
Roche Holding Liabilities→
Roche Holding Stock
Roche Holding Equity→
Roche Holding Stock
Roche Holding AAQS→
Roche Holding Stock
Roche Holding Employees→
Roche Holding Stock
Roche Holding ROE→
Roche Holding Stock
Roche Holding ROA→
Roche Holding Stock
Roche Holding ROCE→
Roche Holding Stock
Roche Holding News→
Roche Holding Stock
Roche Holding Analyst Price Targets→